The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
21 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $4,500,257 in first-year total cost, median $211,202.
Most frequent study sections
- Special Emphasis Panel[ZAI1 LR-M (S1)]21
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2
- BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)1
- CLEMSON UNIVERSITY1
- IOWA STATE UNIVERSITY1
- JOHNS HOPKINS UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Trehalose-6-phosphate phosphatase inhibitors as anti-helminthics1R21AI127623-01 | ALLEN, KAREN N. | BOSTON UNIVERSITY (CHARLES RIVER CAMPUS), MA | $264,607 | ZAI1 |
| 2017 | Novel Therapeutics for Treatment of River Blindness and Lymphatic Filariasis1R21AI127639-01 | SAKANARI, JUDY | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $263,752 | ZAI1 |
| 2017 | Structure- and ligand-based design of new IspD-targeting antimalarials1R21AI128362-01 | CARLIER, PAUL R | VIRGINIA POLYTECHNIC INST AND ST UNIV, VA | $245,526 | ZAI1 |
| 2017 | Discovery of Novel Therapeutics for Fungal Pathogens1R21AI127570-01 | KIM, KWANG S | JOHNS HOPKINS UNIVERSITY, MD | $244,813 | ZAI1 |
| 2017 | Targeting trypanosomatid deoxyhypusine synthase1R21AI127503-01 | PHILLIPS, MARGARET A. | UT SOUTHWESTERN MEDICAL CENTER, TX | $243,000 | ZAI1 |
| 2017 | Development of Novel Therapeutics for Leishmaniasis1R21AI127591-01 | GUY, RODNEY KIPLINLANDFEAR, SCOTT M | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $242,748 | ZAI1 |
| 2017 | Parasite-specific proteasome inhibitors to combat multi-drug resistant malaria1R21AI127581-01 | BOGYO, MATTHEW | STANFORD UNIVERSITY, CA | $231,625 | ZAI1 |
| 2017 | Exploiting interspecies/interkingdom communication for the discovery and development of novel natural products antifungal therapeutics1R21AI127640-01 | WANG, CLAY CC | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $226,971 | ZAI1 |
| 2017 | Identification of preclinical drug candidates for the treatment of schistosomiasis1R21AI127635-01 | PETUKHOV, PAVEL ATHATCHER, GREGORY R. JWILLIAMS, DAVID LEE | RUSH UNIVERSITY MEDICAL CENTER, IL | $222,045 | ZAI1 |
| 2017 | Targeting Plasmodium apicoplast DNA replication for the treatment and prevention of malaria1R21AI127622-01 | NELSON, SCOTT W. | IOWA STATE UNIVERSITY, IA | $217,162 | ZAI1 |
| 2017 | Redirected T Cell Therapy to Cure Invasive Fungal Infections1R21AI127381-01 | KONTOYIANNIS, DIMITRIOS PKUMAR, PAPPANAICKEN RANGASAMY | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $211,202 | ZAI1 |
| 2017 | Prevention of Candida biofilms by localized delivery of aurein analogues1R21AI127442-01 | PALECEK, SEAN P | UNIVERSITY OF WISCONSIN-MADISON, WI | $210,436 | ZAI1 |
| 2017 | Novel Inhibitors of Cruzain and Trypanosoma brucei Cathpesin B as Potential Drug Candidates for the Treatment of African Trypanosomiasis and Chagas Disease1R21AI127634-01 | MEEK, THOMAS | TEXAS A&M AGRILIFE RESEARCH, TX | $206,680 | ZAI1 |
| 2017 | Treatment and Prevention of Systemic Candidiasis1R21AI127489-01 | NOBLE, SUZANNE M | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $198,125 | ZAI1 |
| 2017 | A Systems Biology Approach for Targeted Drug Discovery for Leishmaniasis1R21AI127582-01 | IBBA, MICHAELSATOSKAR, ABHAY R | OHIO STATE UNIVERSITY, OH | $195,428 | ZAI1 |
| 2017 | Rational design of CNS-permeable cathepsin L inhibitors for treatment of chronic toxoplasmosis1R21AI127492-01 | CARRUTHERS, VERNON BRUCELARSEN, SCOTT D | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $193,750 | ZAI1 |
| 2017 | Novel Therapeutics Targeting Giardia Kinases1R21AI127493-01 | MERRITT, ETHAN A | UNIVERSITY OF WASHINGTON, WA | $193,386 | ZAI1 |
| 2017 | Development of Gallinamide A-Inspired Agents for the Treatment of Chagas’ Disease1R21AI127505-01 | GERWICK, WILLIAM HENRYSIQUEIRA-NETO, JAIR LAGE | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $192,910 | ZAI1 |
| 2017 | Identification of kinetoplastid parasite glucose uptake and subcellular localization inhibitors as therapeutic leads1R21AI127575-01 | CHRISTENSEN, KENNETH AGOLDEN, JENNIFER E.MORRIS, JAMES CULVINWANG, ZHUO MICHAELWERBOVETZ, KARL A | CLEMSON UNIVERSITY, SC | $184,138 | ZAI1 |
| 2017 | Lead optimization of agents targeting multiple kinetoplastid parasites1R21AI127594-01 | POLLASTRI, MICHAEL P | NORTHEASTERN UNIVERSITY, MA | $159,953 | ZAI1 |
| 2017 | Broad spectrum antifungals targeting fatty acid biosynthesis1R21AI127607-01 | PALMER, GLEN | UNIVERSITY OF TENNESSEE HEALTH SCI CTR, TN | $152,000 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.